Samrat Pharmachem Ltd
₹ 482
-1.89%
30 May
- close price
About
Samrat Pharmachem Ltd is primarily engaged in manufacturing of various types of Iodine compounds.[1]
Key Points
- Market Cap ₹ 149 Cr.
- Current Price ₹ 482
- High / Low ₹ 1,250 / 332
- Stock P/E 8.96
- Book Value ₹ 204
- Dividend Yield 0.21 %
- ROCE 34.9 %
- ROE 30.2 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 38.9% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
70 | 72 | 65 | 47 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | |
63 | 71 | 64 | 46 | 62 | 69 | 87 | 108 | 131 | 170 | 197 | 287 | |
Operating Profit | 6 | 1 | 1 | 1 | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 |
OPM % | 9% | 2% | 1% | 2% | 2% | 5% | 6% | 3% | 5% | 5% | 11% | 8% |
0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Profit before tax | 6 | 1 | 0 | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 |
Tax % | 35% | 31% | 41% | 35% | 33% | 37% | 35% | 29% | 27% | 27% | 27% | 26% |
Net Profit | 4 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 |
EPS in Rs | 12.23 | 1.29 | 0.78 | 1.04 | 0.97 | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 27% |
3 Years: | 31% |
TTM: | 40% |
Compounded Profit Growth | |
---|---|
10 Years: | 45% |
5 Years: | 39% |
3 Years: | 58% |
TTM: | -3% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | 29% |
3 Years: | 88% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 28% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Reserves | 9 | 10 | 10 | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 |
3 | 4 | 3 | 3 | 6 | 7 | 9 | 7 | 9 | 9 | 8 | 19 | |
16 | 17 | 15 | 10 | 17 | 14 | 13 | 14 | 25 | 19 | 30 | 34 | |
Total Liabilities | 32 | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 |
4 | 4 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | |
CWIP | 3 | 4 | -0 | -0 | -0 | 0 | -0 | -0 | 1 | -0 | -0 | -0 |
Investments | -0 | -0 | -0 | -0 | 2 | -0 | -0 | -0 | -0 | -0 | 0 | 2 |
25 | 27 | 24 | 19 | 27 | 29 | 34 | 33 | 50 | 48 | 75 | 104 | |
Total Assets | 32 | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | -2 | 4 | -1 | -0 | -3 | 0 | 2 | -1 | 5 | 18 | ||
-4 | -1 | -0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | ||
2 | 1 | -1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | ||
Net Cash Flow | 2 | -2 | 2 | -0 | -0 | -1 | -1 | 1 | -1 | -0 | 14 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 60 | 63 | 74 | 93 | 59 | 86 | 69 | 74 | 67 | 72 | 60 |
Inventory Days | 46 | 54 | 45 | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 |
Days Payable | 86 | 89 | 87 | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 |
Cash Conversion Cycle | 15 | 25 | 21 | 36 | 26 | 58 | 70 | 52 | 61 | 53 | 51 | 61 |
Working Capital Days | 27 | 37 | 25 | 39 | 35 | 61 | 65 | 56 | 63 | 54 | 44 | 62 |
ROCE % | 49% | 9% | 7% | 7% | 5% | 16% | 23% | 12% | 22% | 24% | 52% | 35% |
Documents
Announcements
- Disclosure Of Related Party Transactions For The Half Year Ended March 31 2023 5h
- Audited Financial Results For The Year Ended March 31 2023 6h
- Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today 6h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 22 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
19 May - Annual Secretarial Compliance Report for FY 2022-23 issued by Practicing Company Secretary Mr. Aqueel A. Mulla of M/s A. A. Mulla & Associates.
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Offerings
The company's product offerings include various types of iodine compounds[1] which find applications in Pharmaceutical, FMCG, Animal Feed, Chemicals and Agrochemical industries.[2]